Karl Normington, Ph.D.
Karl Normington has more than 25 years of experience in biotechnology and pharmaceutical organizations and the intellectual property field. He currently oversees patent, licensing and strategy evaluation. Prior to joining Palleon, he was Executive Director at Catabasis Pharmaceuticals, where he oversaw the company’s patent portfolio and managed IP due diligence efforts. Prior to Catabasis, Karl was Director of Due Diligence in GlaxoSmithKline’s global patents group, led the IP and licensing efforts at Sirtris Pharmaceuticals and managed the IP portfolio at Alkermes. He has authored several scientific papers and is an inventor on numerous patents. Karl earned a Master of Business Administration degree from UT Dallas, a doctorate in cell and molecular biology from UT Southwestern Medical School, and a Bachelor of Science degree in biology from MIT.